(Reuters) -Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing personal reasons, the Danish drugmaker said on Thursday. Dolsten ...

Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc. The ...

Pfizer's CEO certainly thinks so. In a TV interview, Bourla said: "Pfizer, when it plays, plays big. And we will -- as we did in COVID, as we did with Lipitor, as we did with ... Viagra, as we did ...

Pfizer (PFE) CEO and chairman Albert Bourla told Yahoo Finance Executive Editor Brian Sozzi during Yahoo Finance's annual Investconference that the $10 billion acquisition of GLP-1 maker Metsera (MTSR ...

Pfizer’s battle with Novo Nordisk over control of obesity drug developer Metsera is getting nasty. After Pfizer apparently sealed a $4.9 billion purchase of Metsera in September, Novo Nordisk swooped ...

Nov 13 (Reuters) - Mikael Dolsten, Pfizer's (PFE.N), opens new tab former research and development chief, has withdrawn his candidacy for Novo Nordisk's (NOVOb.CO), opens new tab board, citing ...